Exelixis Q1 Revenue Jumps 10% to $610.81M, EPS Surges 43.6% on Strong CABOMETYX Sales
EXEL sits 33% above its 52-week low of $33.755.
Summary
Exelixis reported robust first-quarter 2026 financial results, with total revenues increasing 10% year-over-year to $610.81 million and diluted EPS surging 43.6% to $0.79. This strong performance, which saw net income rise over 30%, was primarily driven by continued growth in CABOMETYX sales, particularly in key indications like first-line renal cell carcinoma. The positive financial update is complemented by significant pipeline progress, including the FDA's acceptance of an NDA for zanzalintinib with atezolizumab, setting a PDUFA date of December 3, 2026. These results demonstrate sustained operational momentum following strong FY2025 performance and positive FY2026 guidance. Traders will be watching the upcoming PDUFA date for zanzalintinib and the ongoing performance of CABOMETYX.
At the time of this announcement, EXEL was trading at $45.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $33.76 to $49.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.